EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms

Jane T Jones iD, Kaesi A Morelli iD, Elisa M Vesely iD, Charles T S Puerner iD, Chetan K Pavuluri, Brandon S Ross, Norman van Rhijn, Michael J Bromley iD, Robert A Cramer iD

mBio · 31.10.2023 · 14 (5)

DOI: 10.1128/mbio.01516-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 31.10.2023. Verfasst von Jane T Jones und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine , Hanover, New Hampshire, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Mycoses. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIDDK NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

People with cystic fibrosis (pwCF) commonly test positive for the pathogenic fungus Aspergillus fumigatus , which is associated with a decline in lung function. Trikafta is a recently approved therapy for pwCF that improves quantity and function of the CFTR protein; however, it is not known how Trikafta affects microbial communities in the lung. Therefore, the aim of this study was to determine whether Trikafta directly affects A. fumigatus growth and biology. While Trikafta did not impact the viability of A. fumigatus conidia, treatment of A. fumigatus biofilms with Trikafta reduced overall biofilm biomass. This finding was associated with increased membrane permeability, decreased viability, and reduced metabolic activity following long-term treatment of biofilms. Trikafta-induced membrane permeability, and biomass reduction was partially blocked with the calcium channel inhibitor verapamil and fully blocked by the mammalian CFTR inhibitor GlyH-101. Trikafta-induced biomass reduction and metabolic activity was shown to be regulated by the high-osmolarity glycerol pathway gene sakA . Trikafta treatment also induced resistance to the cell wall stressor calcofluor white, susceptibility to the anti-fungal drug caspofungin, and decreased inflammatory responses from murine bone marrow cells. Collectively, these results reveal that Trikafta affects infection-relevant A. fumigatus biology and host-microbial interactions. IMPORTANCE PwCF commonly test positive for pathogenic fungi, and more than 90% of the cystic fibrosis patient population is approved for the modulator treatment, Trikafta. Therefore, it is critical to understand how fungal communities, specifically A. fumigatus , respond to Trikafta exposure. Therefore, we sought to determine whether Trikafta impacted the biology of A. fumigatus biofilms. Our data demonstrate that Trikafta reduces biomass in several laboratory strains as well as clinical strains isolated from the expectorated sputum of pwCF. Furthermore, Trikafta reduces fungal viability and the capacity of biofilms to recover following treatment. Of particular importance, Trikafta affects how A. fumigatus biofilms respond to cell wall stressors, suggesting that Trikafta modulates components of the cell wall. Since the cell wall directly affects how a host immune system will respond to and effectively neutralize pathogens, our work, demonstrating that Trikafta impacts the A. fumigatus cell wall, is potentially highly relevant to fungal-induced disease pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisMycosesHumansAspergillus fumigatusCell WallBiofilmsAminophenolsDrug CombinationsIndolesPyrazolesPyridinesQuinolinesBenzodioxoles

Stichwörter der Autor:innen

Aspergillus fumigatusTrikaftaanti-fungal agentscystic fibrosisdrug susceptibility

Substanzen

elexacaftor, ivacaftor, tezacaftor drug combinationAminophenolsDrug CombinationsIndolesPyrazolesPyridinesQuinolinesBenzodioxoles

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Dartmouth Geisel School of Medicine , Hanover, New Hampshire, USA.
  • Manchester Fungal Infection Group, Division of Evolution, Infection, and Genomics, Faculty of Biology, Medicine and Health, University of Manchester , Manchester, United Kingdom.
  • Antimicrobial Resistance Network, University of Manchester , Manchester, United Kingdom.

ORCID-Profile: Jane T Jones, Kaesi A Morelli, Elisa M Vesely, Charles T S Puerner, Michael J Bromley, Robert A Cramer

Förderung

  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • NIAID NIH HHS
  • Cystic Fibrosis Foundation
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • HHS | NIH | National Institute of General Medical Sciences
  • HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
  • HHS NIH National Institute of Allergy and Infectious Diseases

Zitieren

APA

Jones, J. T., Morelli, K. A., Vesely, E. M., Puerner, C. T. S., Pavuluri, C. K., Ross, B. S., van Rhijn, N., Bromley, M. J., & Cramer, R. A. (2023). The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms. mBio, 14(5). https://doi.org/10.1128/mbio.01516-23

Vancouver

Jones JT, Morelli KA, Vesely EM, Puerner CTS, Pavuluri CK, Ross BS, et al. The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms. mBio. 2023;14(5). doi:10.1128/mbio.01516-23

BibTeX
@article{Jones2023,
  author = {Jones, Jane T and Morelli, Kaesi A and Vesely, Elisa M and Puerner, Charles T S and Pavuluri, Chetan K and Ross, Brandon S and van Rhijn, Norman and Bromley, Michael J and Cramer, Robert A},
  title = {The cystic fibrosis treatment Trikafta affects the growth, viability, and cell wall of Aspergillus fumigatus biofilms},
  journal = {mBio},
  year = {2023},
  volume = {14},
  number = {5},
  doi = {10.1128/mbio.01516-23}
}
Kostenlos starten →